Trial Profile
Efficacy of fixed monthly dosing of Lucentis® (Ranibizumab) on subretinal fluid associated with persistent retinal pigment epithelial detachment in neovascular age-related macular degeneration: An exploratory study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Jun 2018
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms Lucentis IIT
- 19 Jun 2018 New trial record